


Atty. Dkt. No. 072827-2002

In the Claims

Please amend the claims as follows. Claim 40 is amended.

1. (Previously presented) A compound having the chemical formula:



wherein R₁ is selected from the group consisting of: heteroaryl and heterocycloalk;

R₂ is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =O, C(O)OH, C(O)O-lower alk, C(O)NH-lower alk, C(O)N(lower alk)₂, SH, S-lower alk, NH₂, NH-lower alk, and N(lower alk)₂,

R₃ and R₄ is each independently lower alk or together cyclopropyl;

R₅ is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, or a substituted phenyl having one to four substituents with at least one substituent in a *meta* or *para* position selected from the group consisting of: lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy,

provided that said substituted phenyl may also have 2 to 3 additional substituents;

R₆ if present is either hydrogen, lower alkyl or lower alkenyl, wherein R₆ is not present if R₂ is =O;

Atty. Dkt. No. 072827-2002

Y_1 is either covalent bond, alkylene, or alkenylene;

Y_2 is alkylene;

Y_3 is alkylene;

Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene,

provided that R_1 is not pyridyl, benzydioxy, or thiophene;

provided that if Z is either O, S, NH, or N-lower alk, then Y_1 is not a covalent bond; further provided that Y_1 and Z may together be a covalent bond;

further provided that if R_5 is 3, 4 dimethoxy-phenyl, then R_1 is not benzo(d)isothiazole;

further provided that if R_5 is 4-methoxy-phenyl, then R_1 is not 4-benzo(d)isothiazole;

further provided that if R_5 is 4-Cl-phenyl, then R_1 is not pyridyl; 1-imidazole; or 4-benzo(d)isothiazole; and

pharmaceutically acceptable salts and complexes thereof;

wherein said compound has an $IC_{50} \leq 10 \mu M$ using the Calcium Receptor Inhibitor Assay.

2. (Original) The compound of claim 1, wherein:

Y_1 is methylene;

Y_2 is methylene; and

Y_3 is methylene.

Atty. Dkt. No. 072827-2002

3. (Original) The compound of any of claims 1-2, wherein

R₂ is OH or methoxy,

R₆ is hydrogen,

R₃ or R₄ is independently methyl or ethyl; and

Z is O, S, or unsubstituted alkylene.

4. (Original) The compound of claim 3, wherein R₂ is OH, and Z is O.

5. (Original) The compound of claims 1-2, wherein

R₂ is hydrogen,

R₆ is hydrogen,

R₃ and R₄ is independently methyl or ethyl; and

Z is O or methylene.

6. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claims 1-2.

7-31 (Cancelled)

32. (Previously presented) The compound of claim 1 wherein R₁ is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinoliny, isoquinoliny, and heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, NO₂, NH₂, and OH.


33. (Previously presented) The compound of claim 3 wherein R₁ is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinoliny, isoquinoliny, and

Atty. Dkt. No. 072827-2002

heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, NO₂, NH₂, and OH.

34. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 3.

35. (Previously presented) A compound having the chemical formula:



wherein R₁ is selected from the group consisting of: benzothiopyranyl, carbazole, indolyl, quinoliny, isoquinoliny, and heterocycloalk, optionally substituted with 1 to 4 substituents selected from the group consisting of: alkoxy, lower haloalkyl, S-unsubstituted alkyl, lower haloalkoxy, unsubstituted alkyl, unsubstituted alkenyl, halogen, SH, CN, NO₂, NH₂, and OH;

R₂ is selected from the group consisting of: lower alk, cycloalk, alkoxy, H, OH, =O, C(O)OH, C(O)O-lower alk, C(O)NH-lower alk, C(O)N(lower alk)₂, SH, S-lower alk, NH₂, NH-lower alk, and N(lower alk)₂,

R₃ and R₄ is each independently lower alk or together cyclopropyl;

R₅ is either an optionally substituted naphthyl having one to four substituents independently selected from the group consisting of methyl, ethyl, isopropyl, methoxy, Cl, F, Br, and lower haloalkoxy, or a substituted phenyl having one to four substituents with at least one substituent in a *meta* or *para* position selected from the group consisting of:

Atty. Dkt. No. 072827-2002

lower alkyl, methoxy, Cl, F, Br, and lower haloalkoxy, provided that said substituted phenyl may also have 2 to 3 additional substituents;

R₆ if present is either hydrogen, lower alkyl or lower alkenyl, wherein R₆ is not present if R₂ is =O;

Y₁ is either covalent bond, alkylene, or alkenylene;

Y₂ is alkylene;

Y₃ is alkylene;

Z is selected from the group consisting of: covalent bond, O, S, NH, N-lower alk, alkylene, alkenylene, and alkynylene, provided that if Z is either O, S, NH, or N-lower alk, then Y₁ is not a covalent bond; further provided that Y₁ and Z may together be a covalent bond; and

pharmaceutically acceptable salts and complexes thereof;

wherein said compound has an IC₅₀ ≤ 10 μM using the Calcium Receptor Inhibitor Assay.

36. (Previously presented) The compound of claim 35, wherein:

Y₁ is methylene;

Y₂ is methylene; and

Y₃ is methylene.

37. (Previously presented) The compound of any of claims 35-36, wherein

R₂ is OH or methoxy,

R₆ is hydrogen,

Atty. Dkt. No. 072827-2002

R₃ or R₄ is independently methyl or ethyl; and

Z is O, S, or unsubstituted alkylene.

38. (Previously presented) The compound of claim 36, wherein R₂ is OH, and Z is O.

39. (Previously presented) The compound of claims 35-36, wherein

R₂ is hydrogen,

R₆ is hydrogen,

R₃ and R₄ is independently methyl or ethyl; and

Z is O or methylene.

40. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claims 35-36 and ~~39~~ 38.